Table 3.

Prognostic factors in EGFR‐mutant non‐small cell lung cancer patients without brain metastasis according to univariate and multivariate analyses

	Progression‐free survival				Overall survival
	Univariate analysis		Multivariate analysis		Univariate analysis		Multivariate analysis
Variables	HR, mean (95% CI)	P‐value	HR, mean (95% CI)	P‐value	HR, mean (95% CI)	P‐value	HR, mean (95% CI)	P‐value
Age (<75/≥75 years)	0.70 (0.37–1.34)	0.281	—	—	1.40 (0.66–2.98)	0.377	—	—
Sex (male/female)	1.32 (0.70–2.48)	0.395	—	—	1.31 (0.62–2.78)	0.482	—	—
Performance status (0–1/2)	1.91 (0.45–7.99)	0.368	—	—	1.94 (0.86–4.36)	0.104	—	—
Smoking status (smoker/never smoker)	1.84 (0.91–3.71)	0.085	—	—	0.94 (0.22–4.00)	0.938	—	—
Histological subtype (adenocarcinoma/squamous cell carcinoma)	0.17 (0.02–1.38)	0.059	—	—	0.32 (0.04–2.43)	0.242	—	—
Stage (postoperative relapse/stage IIIB, IVA, IVB)	0.50 (0.24–1.02)	0.051	—	—	0.32 (0.13–0.83)	0.014	0.49 (0.17–1.38)	0.175
EGFR mutation status (exon 19 deletion/Exon 21 L858R)	0.84 (0.45–1.58)	0.593	—	—	0.96 (0.45–2.02)	0.907	—	—
EGFR‐TKI (gefitinib/erlotinib)	1.67 (0.40–6.98)	0.478	—	—	Not evaluable	0.080	—	—
No. metastatic organs (≥2/1)	6.49 (2.31–18.24)	<0.001	12.60 (2.18–72.96)	0.005	4.12 (1.14–14.95)	0.020	4.94 (1.23–19.87)	0.025
Bone metastasis (positive/negative)	1.45 (0.75–2.80)	0.269	—	—	1.08 (0.47–2.47)	0.859	—	—
Liver metastasis (positive/negative)	4.42 (1.45–13.46)	0.004	0.66 (0.11–4.05)	0.656	3.84 (0.85–17.4)	0.060	—	—
Pleural effusion (positive/negative)	2.29 (1.11–4.73)	0.020	2.98 (1.40–6.35)	0.005	3.00 (1.35–6.68)	0.005	2.79 (1.14–6.83)	0.025